Completed PHASE2 INTERVENTIONAL 2-arm NCT01639300

Safety Study of GNbAC1 in Multiple Sclerosis Patients

Randomised Placebo-Controlled Single Blind Study to Investigate Single Ascending Doses of GNbAC1 in Multiple Sclerosis Patients Followed by Open-label Extension With Repeated Doses of GNbAC1

Sponsor: GeNeuro Innovation SAS

Conditions Multiple Sclerosis

Interventions GNbAC1 GNbAC1 placebo

Updated 7 times since 2017 Last updated: Feb 5, 2021 Started: Jul 31, 2012 Primary completion: Apr 30, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Sclerosis, this trial is completed. The trial is conducted by GeNeuro Innovation SAS and has accumulated 7 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Mar 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Mar 2021 [monthly]

Completed PHASE2
Oct 2020 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Oct 2020 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GeNeuro Innovation SAS

Data source: GeNeuro SA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Basel, Switzerland
• Geneva, Switzerland